“In the pharmaceuticals segment, every company seems to be a different sector in itself. We are very optimistic in the pharmaceutical manufacturing or CDMO space where we see a multi-year scalable opportunity for the Indian companies. On the generic side, we are very choosy. We have exposure in limited names.”